MT2007-12 Allogeneic Natural Killer Cells With Rituximab in Patients With CD20 Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. Strategies to Increase Sensitivity of CLL Tumor Cells to Natural Killer Cell-Immune-Mediated Cytolysis

Trial Profile

MT2007-12 Allogeneic Natural Killer Cells With Rituximab in Patients With CD20 Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. Strategies to Increase Sensitivity of CLL Tumor Cells to Natural Killer Cell-Immune-Mediated Cytolysis

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Lymphokine-activated killer cells (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top